Bevacizumab biosimilar - Biocon/Mylan

Drug Profile

Bevacizumab biosimilar - Biocon/Mylan

Alternative Names: MYL 1402O

Latest Information Update: 08 Jul 2017

Price : $50

At a glance

  • Originator Biocon
  • Developer Biocon; Mylan
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Colorectal cancer; Non-small cell lung cancer
  • Phase I Cancer

Most Recent Events

  • 30 May 2017 Pharmacokinetics and Adverse events data from a phase I trial in Healthy volunteers presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Europe (IV)
  • 07 May 2015 Phase-III clinical trials in Non-small cell lung cancer in India (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top